Microbion enrolled the first patient in its U.S. Phase IIA study of MBN-101 candidate for treatment of orthopaedic implant-related infections.
MBN-101 is the lead in a new class of drugs under development by Microbion to combat infections, including multi-drug-resistant strains. The study is partially funded by a grant from the U.S. Department of Defense (DOD), Military Infectious Diseases Research Program and managed by the University of Pennsylvania. DOD has provided grants to Microbion in the past.
Numerous anti-infection approaches are in varying stages of development, such as BONESUPPORT’s drug-eluting bone substitute, PolyPid’s bone void filler, Silver Bullet’s antimicrobial devices, Tyber Medical’s BioTy surface treatment; that’s not even including the use of disposable instruments. The topic is of critical importance to just about every stakeholder along the chain of product commercialization.
Sources: Microbion Corporation, ORTHOWORLD Inc.
Microbion enrolled the first patient in its U.S. Phase IIA study of MBN-101 candidate for treatment of orthopaedic implant-related infections.
MBN-101 is the lead in a new class of drugs under development by Microbion to combat infections, including multi-drug-resistant strains. The study is partially funded by a grant from the U.S. Department...
Microbion enrolled the first patient in its U.S. Phase IIA study of MBN-101 candidate for treatment of orthopaedic implant-related infections.
MBN-101 is the lead in a new class of drugs under development by Microbion to combat infections, including multi-drug-resistant strains. The study is partially funded by a grant from the U.S. Department of Defense (DOD), Military Infectious Diseases Research Program and managed by the University of Pennsylvania. DOD has provided grants to Microbion in the past.
Numerous anti-infection approaches are in varying stages of development, such as BONESUPPORT’s drug-eluting bone substitute, PolyPid’s bone void filler, Silver Bullet’s antimicrobial devices, Tyber Medical’s BioTy surface treatment; that’s not even including the use of disposable instruments. The topic is of critical importance to just about every stakeholder along the chain of product commercialization.
Sources: Microbion Corporation, ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.